Are peptides legal in South Dakota?

Can a South Dakota resident get peptides by telehealth?

SDCL chapter 34-52 (Telehealth Utilization by Health Care Professionals, enacted 2021) defines telehealth to include interactive audio-video, audio combined with store-and-forward technology, and remote monitoring, and it defines store-and-forward as information stored for asynchronous delivery of care. The professional must be licensed in South Dakota (or work for a qualifying facility), and telehealth may not be used without a proper provider-patient relationship, which under SDCL 34-52-3 includes verifying the patient's identity, disclosing the provider's credentials, obtaining consent, establishing a diagnosis through examination and any needed testing, discussing treatment options, arranging follow-up, and using technology adequate to evaluate the condition. SDCL 34-52-6 bars prescribing a controlled substance solely in response to an internet questionnaire or telephone consult without such a relationship; GLP-1 medicines and the peptides in this database are not controlled, but the examination element of 34-52-3 still applies. Whether a purely asynchronous encounter can establish the relationship is not expressly resolved, so this record marks it as unresolved. [2]

How does the South Dakota pharmacy board treat compounding?

The South Dakota Board of Pharmacy licenses pharmacies and pharmacists under SDCL chapter 36-11 and regulates practice through Administrative Rules of South Dakota article 20:51, with compounding practices in chapter 20:51:31. SDCL 36-11-19.3 requires any nonresident pharmacy to be licensed before doing business in South Dakota, to be licensed and in good standing in its home state, and to submit its most recent home-state inspection report, so an out-of-state pharmacy shipping to South Dakota patients needs a South Dakota nonresident license. The compounding chapter was rewritten effective June 2, 2024, when the older sterile compounding rules (20:51:31:02 to 20:51:31:31) were repealed, and amended again effective September 15, 2025 (52 SDR 27): rule 20:51:31:32 now requires all sterile and nonsterile compounding to follow federal law and the February 1, 2024 USP chapters 797, 795, 800, and 825, and rules 20:51:31:33 and 20:51:31:34 require a compounding policy and procedure manual with a quality assurance program and USP physical, equipment, and environmental standards. South Dakota has not adopted its own list of compoundable bulk substances; the federal 503A test applies (approved drug component, USP or NF monograph, or FDA 503A bulks list). [1] [3] [4] [5] [6]

Can you get compounded GLP-1s in South Dakota?

South Dakota has not published a state rule that is looser than FDA policy. Because many South Dakota patients use mail order, confirming that the dispensing pharmacy holds a South Dakota nonresident license is the main practical check. [1] [3] [9]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in South Dakota?

Find a provider in South Dakota

• Compounding pharmacies in South Dakota
• Clinics in South Dakota
• Telehealth providers in South Dakota

Is it legal to buy research peptides in South Dakota?

SDCL chapter 36-11 reserves dispensing of prescription drugs to licensed pharmacies and pharmacists, so shipping "research use only" injectable peptides to South Dakota consumers is not a licensed pharmacy activity. [3] [10]

Peptide-specific notes for South Dakota

No peptide-specific rule identified for this jurisdiction. The general compounding and telehealth rules above apply, and the federal record covers semaglutide, tirzepatide, and BPC-157.

Frequently asked questions

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, and federal FDA guidance.